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ost-Conditioning for
ardioprotection During
eperfusion Therapy
oo Good to Be True?*
bhiram Prasad, MD
ochester, Minnesota
eperfusion Injury
he extent of myocardial salvage from reperfusion therapy
n ST-segment elevation myocardial infarction (STEMI)
ay be limited by microvascular dysfunction and lethal
eperfusion injury (1,2). Reperfusion injury is the phenom-
non that describes myocardial and vascular damage occur-
ing as a direct consequence of the restoration of blood flow
o the ischemic tissue. Cellular mechanisms that promote
eperfusion injury are incompletely understood (3). Recent
vidence suggests that opening of the mitochondrial perme-
bility transition pore, a nonselective high conductance
hannel of the inner mitochondrial membrane, may repre-
ent a final common pathway by which various upstream
See page 49
riggers cause cell death (4). The channels are closed during
he initial ischemic insult. However, experimental data
uggest that the pores open almost immediately upon the
stablishment of reperfusion, which results in the collapse of
he mitochondrial membrane potential and uncouples oxi-
ative phosphorylation, leading to depletion of adenosine
riphosphate and cell death. It is possible to inhibit reper-
usion injury in animal models using a variety of pharma-
ological and nonpharmacological strategies. In contrast,
ranslation into clinical practice has been disappointing with
early all human studies of adjunctive therapies for modi-
ying reperfusion injury failing to demonstrate cardiopro-
ective benefits (5). Understandably, this has raised doubt
bout the clinical relevance of the concept.
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.t
From the Division of Cardiovascular Diseases and the Department of Internal
edicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota.schemic Pre-/Post-Conditioning
ardiac ischemic pre-conditioning is a mechanical interven-
ion described 2 decades ago in which several brief cycles of
schemia-reperfusion of the heart, before the lethal ischemic
nsult, appears to activate endogenous protective mecha-
isms against reperfusion injury (6). However, its clinical
pplication has not been feasible because of the need to
nitiate pre-conditioning before the onset of STEMI. In-
erest in the field has been rekindled by the demonstration
n animals that application of brief cycles of ischemia-
eperfusion to the heart at the time of reperfusion may also
e effective, and this form of modified reperfusion has been
alled post-conditioning (7). The mechanisms by which
ost-conditioning operates are not known but they probably
nvolve several triggers and mediators. Endogenous opiates
ay represent such a trigger that inhibits mitochondrial
ermeability transition pore opening. Despite its promise,
ost-conditioning of the heart is limited by the fact that it
an only be applied after the patient reaches the cardiac
atheterization laboratory. A potential solution to this
roblem is remote ischemic post-conditioning in which
schemia-reperfusion of a distant tissue or organ may confer
ardioprotection (8).
In this issue of JACC: Cardiovascular Interventions, Rent-
ukas et al. (9) present data from a single center trial of
emote ischemic “periconditioning” among 96 patients with
TEMI subjected to primary percutaneous coronary inter-
ention (PCI). Patients were randomized to 1 of 3 strate-
ies: 1) adjunctive periconditioning; 2) adjunctive pericon-
itioning and morphine; or 3) neither. Periconditioning was
he preferred term for the intervention as it was performed
efore (on average 8 min) reperfusion rather than at the
ime of reperfusion. Three cycles of 4 min of forearm
schemia followed by 4 min of reperfusion were performed.
he primary end point (proportion of patients with com-
lete ST-segment resolution 1 h after PCI, defined as
80% reduction in the cumulative ST-segment shift on the
2-lead electrocardiogram) was more often achieved in the
groups with periconditioning than with the control group.
he administration of morphine within 5 min of PCI, in
onjunction with periconditioning, did not lead to a higher
requency of the primary end point compared to pericondi-
ioning alone, though there was a trend in that direction.
he percentage of ST-segment resolution (a secondary end
oint) was significantly higher in those with combined
ericonditioning and morphine therapy than in those re-
eiving periconditioning alone. Peak troponin levels, which
ppeared to have been measured as part of the clinical
ractice rather than at pre-defined time intervals to calculate
n area under the curve, showed lower values in the 2
ericonditioning groups. However, there was no significant
ifference in the peak troponin levels between the 2 active
reatment arms. In summary, the findings of this trial
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57rovide “proof of concept” for the cardioprotective effects of
emote post-conditioning as an adjunctive therapy during
echanical reperfusion in humans.
Several important aspects of the trial design deserve closer
ttention. First, only patients presenting within 6 h of
ymptom onset were included. The mean duration of
schemia was a little over 2 h in each group. This is relevant
ecause most previous studies investigating cardioprotective
trategies have not focused on patients with short ischemic
imes. It is possible that there is an optimal window for
ardioprotection because patients who present very early
e.g., 2 h) and receive effective reperfusion therapy have
mall infarcts and gain little additional benefit from adjunc-
ive therapies, whereas those presenting late (e.g., 6 h)
ustain large infarcts and may have little potential for
yocardial salvage (2). Thus, the results of the trial cannot
e applied to patients with prolonged symptom onset to
resentation times. Second, periconditioning was initiated
ithin 10 min of reperfusion. Whether such an intervention
ould be more or less effective if initiated at an earlier time
oint, for example, during transport in the ambulance, is an
mportant question that cannot be addressed by the study by
entoukas et al. (9). However, preliminary data from a
andomized trial among 333 patients suggest that pre-
ospital forearm remote post-conditioning performed dur-
ng transportation in the ambulance may indeed increase
yocardial salvage following primary PCI (10). Third,
igh-risk patients were excluded and therefore the results
annot be extrapolated to patients in cardiogenic shock or
oderate-to-severe renal failure, among others. Fourth, as
cknowledged by the investigators, surrogate end points
ST-segment resolution and peak troponin level as a marker
f infarct size) were used, and whereas these correlate with
linical outcomes, the sample size of the study was insuffi-
ient to evaluate the influence of remote post-conditioning
n “hard” end points. Fifth, PCI was performed very
fficiently with a mean door-to-balloon time of 60 min,
hich confirms that post-conditioning need not delay
eperfusion therapy, and that the results cannot be extrap-
lated to patients with prolonged door-to-balloon times.
inally, the trial does not provide any convincing evidence
hat opiates mediate post-conditioning. Ideally, an opiate
ntagonist such as naloxone should be used to investigate
he role of the opiate receptors, but this is not feasible in
TEMI due to the need for administering opiates for pain
elief.
onclusions
here is accumulating evidence that post-conditioning or
ericonditioning, either performed directly in the heart or
emotely, may confer clinically meaningful benefits. How-
ver, our enthusiasm must be tempered because the human data are derived from small, single center studies. If the
ffect is real, the magnitude of the benefit is remarkably
arge (35% relative reduction in infarct size) in an era in
hich it is increasingly difficult to demonstrate additional
enefits of new therapies beyond current management due
o relatively small infarct size and low mortality of patients
ith STEMI enrolled in clinical trials. If the field is to move
orward, large multicenter clinical trials of cardiac and
emote post-conditioning that have adequate statistical
ower to detect a reduction in clinical end points must be
erformed. The obvious challenge is how to fund these trials
ecause there is limited incentive for industry support
ithout intellectual property rights. On a positive note, the
ample size needed may be reasonable given the magnitude
f the cardioprotective effect seen in the preliminary studies,
hough one cannot help but wonder if it is too good to be
rue!
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ayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
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